Update on Islet Transplantation
Update on Islet Transplantation
复制标题
DOI：
10.1101/cshperspect.a007823
复制
发表时间：
2012-07-01
影响因子：
5.4
通讯作者：
Shapiro, A. M. James
中科院分区：
文献类型：
--
作者：
McCall, Michael;Shapiro, A. M. James
在过去的12年中，临床胰岛移植取得了相当大的进展，在这段时间内，国际上有超过750名1型糖尿病患者接受了胰岛移植。许多国家开始接受从研究到公认和资助的临床护理的过渡，特别是对于那些控制脆弱，无法通过更传统的手段稳定的患者。主要的挑战仍然存在，包括需要一个以上的捐助者，并要求有效的，长期的免疫抑制。结合对同种异体和自身抗原的免疫耐受性，以及干细胞或异种移植物衍生的胰岛素分泌细胞的无限可扩展来源，代表了将这种有效治疗转移到所有1型或2型糖尿病患者的潜在治疗中的剩余障碍。
Clinical islet transplantation has progressed considerably over the past 12 years, and >750 patients with type 1 diabetes have received islet transplants internationally over this time. Many countries are beginning to accept the transition from research to accepted and funded clinical care, especially for patients with brittle control that cannot be stabilized by more conventional means. Major challenges remain, including the need for more than one donor, and the requirement for potent, chronic immunosuppression. Combining immunological tolerance both to allo- and autoantigens, and a limitless expandable source of stem cell- or xenograft-derived insulin-secreting cells represent remaining hurdles in moving this effective treatment to a potential cure for all those with type 1 or 2 diabetes.